Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | AHR | P35869 | 1/20 | 0.60 |
| ▸ | PTGES | O14684 | 3/20 | 0.55 |
| ▸ | USP8 | P40818 | 3/20 | 0.53 |
| ▸ | USP7 | Q93009 | 1/20 | 0.53 |
| ▸ | USP47 | Q96K76 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432454 | 1.00 | RAB9A (0.60) | RAB9AMAPTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL9672898 | 0.79 | ALDH1A1 (0.54) | RAB9AMAPTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL7918737 | 0.79 | MEN1 (0.52) | RAB9AMAPTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL8238836 | 0.78 | RAB9A (0.62) | RAB9AMAPTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL15032479 | 0.78 | RAB9A (0.61) | RAB9AMAPTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL31696105 | 0.78 | PTGES (0.52) | RAB9AMAPTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL31696139 | 0.78 | USP7 (0.59) | RAB9AMAPTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL7984622 | 0.78 | PTGES (0.52) | RAB9AMAPTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL7998365 | 0.78 | USP7 (0.59) | RAB9AMAPTSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL7998771 | 0.77 | RAB9A (0.60) | RAB9AMAPTSMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001079209-A2 | DIAZAFLUORENONE IL-8 ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | claimed |
| US-20250236841-A1 | METHODS TO ENHANCE TUMOR IMMUNOGENICITY AND COMPOSITIONS FOR AUTOLOGOUS CANCER IMMUNOTHERAPEUTIC PRODUCTS USING MODIFIED TUMOR CELLS AND MODIFIED DENDRITIC CELLS | AIVITA BIOMEDICAL INC (US) | 2025-07-24 | — | — | US | disclosed |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| WO-2023225558-A1 | INHIBITORS OF RLIP76 | AVESTA76 THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| EP-4140485-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20220347277-A1 | Methods to Enhance Tumor Immunogenicity and Compositions for Autologous Cancer Immunotherapeutic Products Using Modified Tumor Cells and Modified Dendritic Cells | AIVITA BIOMEDICAL INC (US) | 2022-11-03 | — | — | US | disclosed |
| EP-3166607-B1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2022-03-03 | — | — | US | disclosed |
| US-11116774-B2 | Modulators of toll-like receptors for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3822637-A1 | METHOD FOR DETERMINING PARP INHIBITOR RESPONSIVENESS AND IMPROVING PARP INHIBITOR THERAPY | Universität Zürich (CH) | 2021-05-19 | — | — | EP | disclosed |
| US-8785452-B2 | Anti-infective compounds | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2014-07-22 | — | — | US | disclosed |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | ACADEMIA SINICA (TW) | 2013-06-20 | — | — | US | disclosed |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | ACADEMIA SINICA (TW) | 2013-06-20 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-20110178077-A1 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2011-07-21 | — | — | US | disclosed |
| US-7659277-B2 | Ubiquitin ligase inhibitors and methods related thereto | Proteologies, Ltd. (IL) | 2010-02-09 | — | — | US | disclosed |
| US-7659277-B2 | Ubiquitin ligase inhibitors and methods related thereto | Proteologies, Ltd. (IL) | 2010-02-09 | — | — | US | disclosed |
| US-20070015768-A1 | Ubiquitin ligase inhibitors and methods related thereto | PROTEOLOGICS, LTD. (IL) | 2007-01-18 | — | — | US | disclosed |
| US-20070015768-A1 | Ubiquitin ligase inhibitors and methods related thereto | PROTEOLOGICS, LTD. (IL) | 2007-01-18 | — | — | US | disclosed |
| WO-2001079209-A2 | DIAZAFLUORENONE IL-8 ANTAGONISTS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11116774-B2 | Modulators of toll-like receptors for the treatment of HIV | TLR7, TLR3, TLR6 | RAB9A 1956/4885MAPT 3071/4885SMN1; SMN2 3549/4885 |
| US-20070015768-A1 | Ubiquitin ligase inhibitors and methods related thereto | XIAP, NEDD4, MDM2 | RAB9A 2331/4885MAPT 352/4885SMN1; SMN2 1125/4885 |
| US-20110178077-A1 | Anti-infective compounds | RABGGTB, ELANE, SERPINB1 | RAB9A 1091/4885MAPT 2660/4885SMN1; SMN2 4839/4885 |
| US-20130158037-A1 | COMPOUNDS AND METHODS FOR TREATING TUBERCULOSIS INFECTION | TALDO1, PGD, DLD | RAB9A 1324/4885MAPT 3251/4885SMN1; SMN2 4689/4885 |
| US-20220062293-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | RAB9A 1956/4885MAPT 3071/4885SMN1; SMN2 3549/4885 |
| US-20240285645-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | TLR7, TLR3, TLR6 | RAB9A 1956/4885MAPT 3071/4885SMN1; SMN2 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.